Dawson James Starts Genprex (GNPX) at Buy

January 30, 2023 7:34 AM EST
Get Alerts GNPX Hot Sheet
Price: $0.81 +2.53%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 15 | Down: 9 | New: 13
Join SI Premium – FREE
(Updated - January 30, 2023 7:46 AM EST)

Dawson James initiates coverage on Genprex (NASDAQ: GNPX) with a Buy rating and a price target of $3.00.

The analyst comments "We project our model out to 2033. We apply a 30% risk cut to our projected revenues in our product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models. We use a fully diluted out year share count assuming multiple raises. The result is equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of $3.00. We note that as the company established proof of concept as a result of clinical trial data, the risk rate (r) is reduced, and valuation rises."

For an analyst ratings summary and ratings history on Genprex click here. For more ratings news on Genprex click here.

Shares of Genprex closed at $1.34 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage